EQS-News: Viromed Medical AG / Key word(s): MiscellaneousViromed Medical AG launches in vivo and ex vivo study with cold plasma on living lungs30.09.2025 / 11:47 CET/CESTThe issuer is solely responsible for the content of this announcement. PRESS RELEASEViromed Medical AG launches in vivo and ex vivo study with cold plasma on living lungsRellingen, September 30, 2025 – Viromed Medical AG ("Viromed"; ISIN: DE000A3MQR65), a medical technology company and pioneer of cold plasma technology, announces the start of a comprehensive in vivo and ex vivo study on living lungs. The detailed results of the in vivo and ex vivo study will be published in a fast-track paper. Viromed Medical AG is a pioneer in the field of cold plasma technology. About Viromed Medical AGViromed Medical AG specializes in the development, manufacture and distribution of medical products.